Drug Channels

JULY 18, 2023

The Humira biosimilar market has arrived! This month, nine biosimilar versions of adalimumab launched in the U.S. Surprisingly, two PBMs—Express Scripts and OptumRx—will each offer at least one low-list-price biosimilar option on their main national formularies. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Biosimilars 78

Biosimilars Pharmacy Marketing Drugs 78

Drug Channels

MARCH 14, 2023

Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Pharmacies and Pharmacy Benefit Managers , our 14th edition, provides a comprehensive, fact-based, and non-partisan tool for understanding the entire U.S. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Pharmacy 87

Pharmacy Drugs Marketing Biosimilars 87

Drug Channels

FEBRUARY 22, 2022

Pharmacies and Pharmacy Benefit Managers. Pharmacies and Pharmacy Benefit Managers is a definitive, nonpartisan resource that includes the most current information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, government regulations, and much more.

Pharmacy 72

Pharmacy Specialty Pharmacies Biosimilars Licensing 72

Drug Channels

DECEMBER 11, 2023

One update: CVS Caremark's 2024 formulary for patient-administered autoimmune products prefers: Humira Hyrimoz (the high WAC Sandoz biosimilar) adalimumab-adaz (the unbranded, low WAC Sandoz biosimilar) Perhaps coincidentally, Sandoz products are marketed by Cordavis, the new business described in today's rerun.

Biosimilars 69

Biosimilars Pharmacy Production Marketing 69

Drug Channels

OCTOBER 31, 2023

CVS Health frightens all but one Humira biosimilar maker away from its formulary. Mark Cuban Cost Plus Drug Company conjures a partnership with Alto Pharmacy. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. The gross-to-net bubble for anti-obesity GLP-1 drugs walks among us. Penn Medicine gorges on the 340B program.

Biosimilars 80

Biosimilars Pharmacy Drugs 80

Drug Channels

JULY 11, 2022

Informa Connect's Hub and Specialty Pharmacy Models West. September 14-15, 2022 Sheraton San Diego Hotel & Marina | San Diego, CA www.informaconnect.com/hub-specialty-pharmacy-west. Copyright © 2006-2022 Pembroke Consulting, Inc. Delivered as a Hybrid Event. Attorney’s Office District of NJ Gustav W.

Specialty Pharmacies 83

Specialty Pharmacies Pharmacy Biosimilars Compliance 83

Drug Channels

NOVEMBER 4, 2024

Here on Drug Channels , we have long highlighted the boom in provider-administered biosimilars. In contrast to the pharmacy market, adoption of these biosimilars is growing, prices are dropping, and formulary barriers continue to fall. As we demonstrate, health plans pay hospitals far above acquisition costs for biosimilars.

Biosimilars 80

Biosimilars Hospitals Pharmacy Production 80

Drug Channels

SEPTEMBER 6, 2023

CVS Health has finally revealed its strategy for biosimilars of AbbVie’s Humira. Rather than announce multiple biosimilars for its pharmacy benefit manager (PBM) formulary, the company will instead launch Cordavis, a new subsidiary that will market a private label, low-list-price version of Sandoz’ Hyrimoz.

Biosimilars 62

Biosimilars Pharmacy Drugs Marketing 62

Drug Channels

FEBRUARY 21, 2023

Pharmacies and Pharmacy Benefit Managers. Pharmacies and Pharmacy Benefit Managers is a definitive, nonpartisan resource that includes the most current information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, government regulations, and much more.

Pharmacy 76

Pharmacy Specialty Pharmacies Licensing Licensing 76

Drug Channels

MARCH 30, 2023

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. So far, it appears that PBMs are neither preferring Amgen's Humira biosimilar nor embracing the low-list/low-rebate version.

Biosimilars 67

Biosimilars Pharmacy Drugs Production 67

Drug Channels

JANUARY 19, 2022

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Each exclusion list contains 400 to 500 products.

Biosimilars 95

Biosimilars Pharmacy Drugs Production 95

Drug Channels

APRIL 29, 2024

April is over, so it's time to hop into this month’s selection of noteworthy news: CVS Health’s formulary boosts a Humira biosimilar An insurer ditches buy-and-bill to save money for plans—but maybe not for patients? Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Specialty Pharmacies 63

Specialty Pharmacies Pharmacy Biosimilars Drugs 63

Drug Channels

AUGUST 23, 2022

on key specialty pharmacy trends Evidence for biosimilar-to-biosimilar switching Plus, Dr. Glaucomflecken takes on PBMs! Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. P.S. Join my more than 31,000 LinkedIn followers for daily links to neat stuff. d/b/a Drug Channels Institute.

Biosimilars 59

Biosimilars Specialty Pharmacies Pharmacy Drugs 59

Drug Channels

MARCH 31, 2022

Along with sunshine and fine weather, this vernal equinox has ushered in a crop of new and noteworthy stories: Health inequities in utilization management Insurers compute big white bagging savings The biosimilar boom accelerates The patient upside of manufacturers’ copay support Whoa. CVS Health takes the red pill. to 1:30 p.m.

Biosimilars 63

Biosimilars Pharmacy Drugs 63

Drug Channels

OCTOBER 27, 2021

It’s the biosimilar boom! Recent posts have covered: Walgreens’ new direction; controversary over independent pharmacy counting; insurer consolidation; retail pharmacy M&A; drug pricing policy; Prime Therapeutics; 340B contract pharmacy litigation; pharmaceutical antitrust; oncology care model; and Peter Bach’s nuptials.

Biosimilars 58

Biosimilars Hospitals Independent Pharmacies Pharmacy 58

Drug Channels

APRIL 3, 2024

The 2024 formularies described below should boost biosimilar adoption. As a new Biosimilar Council report shows , Humira retained 99% of market share in late 2023, despite being more expensive than its biosimilars. This year, Humira and its 14 biosimilars will provide the most intriguing formulary drama.

Biosimilars 52

Biosimilars Pharmacy Drugs Production 52

Drug Channels

APRIL 20, 2022

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars 85

Biosimilars Pharmacy Drugs Production 85

Drug Channels

JANUARY 27, 2023

Saket discusses market access and contracting strategies for medical benefit products when pharmacy benefit biosimilar therapies launch. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. He then describes how to automate formulary and medical policies to protect manufacturers from overpayment.

Biosimilars 77

Biosimilars Pharmacy Therapies Production 77

Drug Channels

MAY 30, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Summer unofficially began over the weekend. Speaking of PBMs, be sure to join me for my new live video webinar, PBMs and the Battle Over Patient Support Funds: Accumulators, Maximizers, and Alternative Funding , on June 23, 2023, from 12:00 p.m. to 1:30 p.m.

Biosimilars 61

Biosimilars Hospitals Pharmacy Drugs 61

Drug Channels

MARCH 5, 2024

WHAT YOU WILL LEARN In 2023, the Inflation Reduction Act of 2022 (IRA) began to alter the Medicare Part D program and trigger changes in beneficiary out-of-pocket spending, drug prices, pharmacy economics, and market access strategies. Pharmacies and Pharmacy Benefit Managers.

Pharmacy 85

Pharmacy Biosimilars Drugs Marketing 85

Drug Channels

NOVEMBER 23, 2021

In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter. Happy Thanksgiving, everyone! to 1:30 p.m.

Specialty Pharmacies 64

Specialty Pharmacies Pharmacy Biosimilars Drugs 64

Drug Channels

JUNE 27, 2021

As you declare your vaccinated independence, celebrate with these Drug Channels fireworks: Amazon’s teeny step toward pharmacy disruption How patients view copay accumulators My $0.02 on generic and biosimilar trends Some hospitals seem to be gaming their 340B eligibility Plus, tips on effective hospital marketing.

Biosimilars 52

Biosimilars Hospitals Pharmacy Vaccine 52

Drug Channels

AUGUST 25, 2021

Time to pack away the bathing suit and get serious again—with these curated curiosities combed from the now-barren Drug Channels beach: OptumRx joins the PBM GPO game Pharmacy DIR fees hit $11 billion A terrific resource on state biosimilar laws Patient views on utilization management Plus, my social media success…from a (print) newspaper ad!

Biosimilars 43

Biosimilars Pharmacy Drugs Research 43

Drug Channels

MAY 27, 2020

Before you venture outside for your lockdown barbeque, check out these noteworthy items off the Drug Channels grill: Payers predict how COVID-19 will affect formularies Our analysis of the 2020 retail-to-mail shift AmerisourceBergen profiles biosimilars Plus, CVS pharmacy offers a clever way to measure appropriate social distancing.

Biosimilars 52

Biosimilars Specialty Pharmacies Pharmacy Hospitals 52

Drug Channels

APRIL 25, 2023

While we wait for the Phillies turnaround, let’s oil up our gloves, lace up our cleats, and run the bases around this month's biggest hits: Foul ball : OptumRx prefers higher prices for the first Humira biosimilar Strikeout : Copay accumulators hurt health equity Bench warmer : Surprise? d/b/a Drug Channels Institute.

Biosimilars 67

Biosimilars Drugs Pharmacy 67

Drug Channels

NOVEMBER 23, 2021

In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S. You can also find my daily posts on LinkedIn , where I have more than 21,000 followers. to 1:30 p.m.

Specialty Pharmacies 61

Specialty Pharmacies Pharmacy Biosimilars Drugs 61

Drug Channels

OCTOBER 25, 2022

Sink your fangs into Amgen’s fantastic new report on the biosimilar boom Wicked! Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Mark Cuban tells ghost stories about PBMs. Walgreens terrifies Wall Street with its 340B losses. Physicians think payers cast evil utilization management spells. d/b/a Drug Channels Institute.

Biosimilars 64

Biosimilars Drugs Pharmacy 64

Drug Channels

NOVEMBER 22, 2021

In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon Plus, the FDA preps you for Thursday with a regulatory soup review. Happy Thanksgiving, everyone! to 1:30 p.m.

Specialty Pharmacies 61

Specialty Pharmacies Pharmacy FDA Biosimilars 61

Drug Channels

JUNE 24, 2020

Before you declare your (socially-distanced) independence, get up close and personal with these Drug Channels fireworks: CVS launches a new GPO for its PBM CMS rethinks copay accumulators Here’s how GoodRx makes money Supermarkets face pharmacy challenges Plus, powerful and important comments from Ken Frazier, CEO of Merck.

Pharmacy 52

Pharmacy Biosimilars Drugs Marketing 52

Drug Channels

NOVEMBER 9, 2022

Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. After the event, every registrant will receive a link to download the complete slide deck and have an opportunity to watch a replay of the live event. Read on for full details on pricing and registration. d/b/a Drug Channels Institute.

Specialty Pharmacies 80

Specialty Pharmacies Pharmacy Biosimilars Drugs 80

Drug Channels

NOVEMBER 24, 2020

In this issue: Rebate rule redux Most Favored Nation and healthcare benchmarking Amazon’s pharmacy customer opportunity Drug spending realities updated GPO consolidation Plus, I congratulate Dirk Rodgers of RxTrace on his retirement. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc. to 1:15 p.m. d/b/a Drug Channels Institute.

Pharmacy 52

Pharmacy Specialty Pharmacies Biosimilars Doctors 52

Drug Channels

NOVEMBER 8, 2021

Join your industry counterparts this December to unravel the complexities of the channel, navigate high-impact topics transforming trade and benchmark winning pharmacy and distribution frameworks. Copyright © 2006-2021 Pembroke Consulting, Inc. Meet The Expert Faculty. Drug Channels, or any of its employees.

Specialty Pharmacies 69

Specialty Pharmacies Pharmacy Biosimilars Marketing 69

Drug Channels

NOVEMBER 14, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Fein will clearly distinguish his opinions and interpretations from the objective facts and data. He will draw from exclusive information found in DCI's economic reports. Read on for full details on pricing and registration. d/b/a Drug Channels Institute.

Pharmacy 77

Pharmacy Biosimilars Drugs Marketing 77

Drug Channels

OCTOBER 7, 2024

Pharmacy Transformation Leader of Blue Shield of California as he leads a comprehensive discussion on the PBM landscape over the last year, and delves into the evolving trends and emerging challenges shaping the current industry today. What can be learned from the economic landscape of biosimilars and specialty therapeutics?

Pharmacy 74

Pharmacy Biosimilars Compliance Marketing 74

Drug Channels

OCTOBER 1, 2024

Last week, the Federal Trade Commission (FTC) released the redacted version of administrative complaint against the three largest pharmacy benefit managers (PBMs). Below, you can review my commentary about the warped incentives behind Viatris’ dual-pricing strategy for its interchangeable biosimilar of Lantus. All rights reserved.

Biosimilars 40

Biosimilars Pharmacy Production FDA 40

Drug Channels

NOVEMBER 29, 2022

In this issue: Mark Cuban schools Elon Musk on PBMs Market access lessons from Semglee Gen Z rejects the pharmacy career path A potent call for 340B transparency Plus, get ready to love the ‘90s again! Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. to 1:30 p.m. Click here to learn more and sign up.

Pharmacy 56

Pharmacy Drugs Marketing Biosimilars 56

Drug Channels

SEPTEMBER 28, 2021

My recent social media topics have included: the ASPE report, biosimilar reimbursement, non-profit hospital shenanigans, HRSA’s reorganization, MTM in Part D, PBMs’ GPOs, pharmacy GPOs, channel strategy, white bagging, and the soothing sounds of pills being counted. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc.

Hospitals 56

Hospitals Biosimilars Pharmacy Drugs 56